XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Royalty Corporation

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on XOMA Royalty Corporation today and set a price target of $97.00. Pantginis cove...

Current Quarter	$0.19	Next Quarter	$0.21
Current Year	$0.94	Next Year	$0.69
QoQ Growth	+10.5%	YoY Growth	-26.6%
3Y EPS CAGR	-63.8%	Target Price	$65.75
Consensus	Buy	Upside	+90.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XOMA	$34.46	-0.35%	130.90K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XOMA	$34.46	-0.3%	130.90K
3
4
5
6

XOMA

XOMA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get XOMA Royalty Corporation Data in Excel

Get XOMA Royalty Corporation Data in Excel